Wockhardt’s inspection of its manufacturing unit located at 57, Kunjhal Barotiwala, Nalagarh, District Solan, Himachal Pradesh by U S Food and Drug Administration (USFDA) has since been completed. Further, no Form 483 has been issued by USFDA in this regard.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
